New mouse models give a boost to the development of cancer immunotherapies

A new cancer treatment called CD40 inhibitor has yielded disappointing results when tested in clinical trials, failing to mobilize patients' immune system against tumors the way it was expected to. But a recent study offers clues about how this experimental drug might be optimized to fulfill its potential.